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Background: Carbapenem resistance among Pseudomonas aeruginosa has become a serious life-threatening problem
due to the limited therapeutic options. In this study, we investigated the prevalence and the molecular epidemiology of
carbapenem resistant Pseudomonas aeruginosa (CRPA) isolated from three hospitals in Annaba city, Algeria.
Methods: During the study period (January, 2012 to December, 2013), all patients infected by P. aeruginosa were
considered as the potential study population. Antibiotic susceptibility testing was performed as recommended
by the CLSI. Screening of carbapenemase producer isolates was performed by using imipenem-EDTA double-disk
synergy test and modified Hodge test. CRPA isolates were tested for the presence of genes encoding β-lactamases,
plasmid mediated quinolone resistance, aminoglycoside resistance and class 1 integrons were investigated by PCR and
sequencing. The clonal relatedness among CRPA isolates was analyzed by pulsed-field gel electrophoresis method. The
clinical data were collected to identify risk factors for CRPA carriage of P. aeruginosa infection.
Results: The overall prevalence of CRPA was 18.75 %. The risk factors for carrying CRPA were the length of hospital stay
(p = 0.04), co-infections with Staphylococcus aureus (p = 0.01), and the use of urinary catheter (p = 0.03). The in-hospital
mortality rate among case patients was 13.33 % compared with 1.53 % for control patients (p = 0.09). All CRPA isolates
were multidrug resistance and the most effective antibiotic against CRPA isolates was amikacin and colistin.
PFGE revealed an epidemic clonal dissemination of CRPA isolates. None of CRPA isolated were found to be
carbapenemase-producers. The blaPSE-1 and aac(3)-II gene was detected in two and five strains respectively. The
class1 integrons were detected in 2 isolates with the presence of aadA7 gene cassette in these integrons.
Conclusion: The endemic clonal dissemination and multi-drug resistance of CRPA isolates in our institution is
highly alarming. Strict measure will be required to control the further spread of these pathogens in hospital
setting.
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Pseudomonas aeruginosa is one of the major opportunistic
and nosocomial pathogen that causes many severe and
often fatal infections, especially in immunocompromised
patients or those with underlying diseases [1]. Multidrug
resistant P. aeruginosa isolates have been detected in hospi-
tals worldwide and associated with increased mortality and* Correspondence: mohammed.timinouni@pasteur.ma
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prolonged treatment with antibiotics [2]. Increasing resist-
ance in P. aeruginosa isolates complicates the selection of
adequate empirical therapy in severe infections. Carbapen-
ems are potent broad spectrum β-lactam antibiotics, and
one of the few remaining agents that have reliable activity
against P. aeruginosa [1–3]. However, increased prevalence
of resistance to carbapenems among these organisms
has been noted [2]. Resistance against carbapenems by
P. aeruginosa may occur through different mechanisms
including: loss of the outer membrane porin OprDrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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efflux-pumps over-expression, and increased produc-
tion of AmpC β-lactamases [1]. Also, P. aeruginosa
may obtain genes encoding carbapenemase enzymes
such as metallo-β-lactamases (MBLs) or Klebsiella
pneumoniae carbapenemase (KPC) [1, 4]. The MBL en-
zymes (IMP, VIM, SPM, GIM, SIM, AIM, FIM, and
NDM) are able to hydrolyze carbapenems efficiently
and thus they are considered as the most clinically sig-
nificant mechanism of carbapenem resistance in P. aer-
uginosa isolates [4]. VIM-type MBLs are predominant
in the Mediterranean region [5, 6]. At Annaba hospital
in Algeria and since December 2010, VIM-2 producing
P. aeruginosa has been isolated, mainly in surgery and
intensive care unit [7, 8]. In 2012, an increasing rate of
imipenem resistance in P. aeruginosa was observed in
Annaba hospitals. The effect of carbapenem resistance
on the outcome of P. aeruginosa infections and risk
factors for acquiring carbapenem resistant P.aeruginosa
(CRPA) in Algeria are unclear. Consequently, the pri-
mary objective of the study was to determine the preva-
lence and molecular characterization of CRPA isolated
from our institution. A secondary objective of the study
was to identify risk factors associated with carbapenem
resistance. It is anticipated that an improved under-
standing of the prevalence, mechanism, and risk factors
of carbapenem resistance in P. aeruginosa may guide
formulary decisions and the choice of empiric therapy
for nosocomial infections in hospitals.Methods and materials
Setting
The study was performed at Annaba university hospital
in Annaba city, Algeria. It is one of the major teaching
hospitals in the eastern part of Algeria and comprised
three affiliated hospitals: Ibn Sina, Dorban and Ibn
Rochd. These three facilities included a 279-bed com-
munity hospital, a 466-bed hospital dedicated especially
to surgical specialities, and the last one with 198-beds,
which serve a diverse spectrum of patients.Data collection
All the patients infected by P. aeruginosa from January,
2012 to December, 2013 were included. The medical
records of these patients were retrieved and reviewed.
Information was obtained about basic demographic
characteristics (age, sex, pre-infection hospital stay, and
nosocomial origin) as well as co-morbid diseases (surgical
intervention, renal diseases, respiratory diseases, central
nervous diseases, and others), presence of previous anti-
biotic use, use of urinary catheters, intensive care unit
admission, previous hospitalization, recent surgery, and
length of hospital stay. The diagnosis of nosocomialinfection was established according to the Center for Dis-
ease Control (CDC) criteria.
Previous hospitalization was defined as hospitalization at
Annaba University or another hospital within 30 days prior
to the current admission. Recent surgery was defined as
any surgical procedure performed in the operating room
within 30 days of entry in the study. The origin of the iso-
late was accepted as nosocomial if the strain was isolated
more than one week after hospitalization.
Microbiological specimens were collected when the
attending physician suspected infection based on systemic
signs (unexplained fever, chills, and hypotension), and/or
local signs (purulent tracheal aspirates in mechanically ven-
tilated patients, purulent urinary drainage, or pus or pain at
a vascular catheter insertion site). Microbiological speci-
mens were collected as recommended by the CDC. Speci-
mens consisted of blood for bacteremia/septicemia, urine
for urinary tract infection, a barncheoalveolar lavage fluid
or endotracheal aspirate for ventilator associated pneumo-
nia and purulent discharges, aspirated pus or drain fluid for
surgical site infection. P. aeruginosa isolated from clinical
specimens were identified using conventional methods as
well as commercial identification kits, API 20NE (Biomer-
ieux, Marcy l’Etoile, France).
The relationship between CRPA strains and the previous
antibiotic therapy was assessed. The antibiotics were
grouped as carbapenems, third-generation cephalosprins,
quinolones, and others. Previous antibiotic therapy was
defined as any systemic antibiotic given at least seven days
within 3 months preceding the isolation of the organism.
In cases of recurrent episodes of P. aeruginosa infections,
only the first event was entered into the database.
Antibiotic susceptibility testing
Antimicrobial drug susceptibility was determined using the
disk diffusion method on Mueller-Hinton (MH) agar plates
(Bio-Rad, Marnes-la-Coquette, France) according to the
recommendations of the Clinical and Laboratory Standards
Institute (CLSI, 2012) [9]. Ten antibiotics were tested,
including ticarcillin, piperacillin, ticarcillin/clavulanic acid,
ceftazidime, imipenem, aztreonam, amikacin, gentamicin,
ciprofloxacin, and colistin. P. aeruginosa ATCC 27853 was
used as a wild-type susceptible control.
Minimum inhibitory concentrations (MICs) of imipenem
were determined using an Etest-strip (AB BioMerieux,
France), as described by the manufacturers’ instructions.
Phenotypic detection of the carbapenemase production
The phenotypic detection of the carbapenemase produc-
tion was performed by the modified Hodge test by using
an imipenem disc (10 μg) as was described by CLSI. The
detection of metallo-β- lactamase production was also
performed by the combined-disc test by using two imipe-
nem discs (10 μg), one containing 10 μL of 0.1 M (292 μg)
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which were placed 25 mm apart on a MH agar plate. An
increase in the zone diameter of >4 mm around the
imipenem-EDTA disc as compared to that of the imipe-
nem disc alone was considered as positive for metallo-β-
lactamase production.
Phenotypic detection of the AmpC and ESBL production
in CRPA isolates
Extended spectrum β-lactamase (ESBL) production was
detected by the double-disc synergy test (DDST) using cla-
vulanic acid-ticarcillin (20/10 mg) and ceftazidime (30 mg)
and aztreonam (30 mg) on MH agar as described by
Hakemi Vala et al. [10]. Phenotypic detection of ESBLs can
be obscured by the chromosomal AmpC cephalosporinase
in P. aeruginosa, hence cloxacillin-containing DDST was
performed. Cloxacillin (250 μg/mL; Sigma, St Louis, MO,
USA) was added in MH agar to inhibit cephalosporinase
activity [11].
AmpC overproduction was confirmed according to the
method of Rodrίguez-Martίnez et al. [11]. The isolates
were considered as AmpC overproduction when there
was at least a twofold dilution difference between the
MICs of ceftazidime, imipenem and the MICs of ceftazi-
dime, imipenem plus cloxacillin [11].
Preparation of DNA template for PCR
Total DNA was extracted by suspending a few colonies of
overnight culture of P.aeruginosa isolates growing on Luria
Bertani agar (Bio-Rad, Marnes-la-Coquette, France) in
500 μL of DNase- and RNase-free water (Invitrogen,
Paisley, UK). The suspension was boiled at 100 °C for
10 min in thermal block (Polystat 5, Bioblock Scientific,
France), then centrifuged at 19000 x g for 5 min. An
aliquot of 1 μL of the supernatant was used as the
DNA template for PCR.
Detection of β-lactamases encoding genes
All CRPA isolates were screened by PCR for the following
carbapenem hydrolysing enzymes encoding genes: blaVIM,
blaIMP, blaGES, blaKPC, blaOXA-58, blaOXA-40, blaOXA-23 and
blaOXA-51 and others β-lactamases : blaTEM, blaSHV, blaSPE-1
and blaOXA-1 as described previously [8, 12, 13]. CRPA
resistance to ceftazidime antibiotic was further tested
by using primers specific for plasmid mediated AmpC
β-lactamase encoding genes as described by Pérez-
Pérez and Hanson [14].
Detection of class 1 integrons
PCR was performed using primers CS-3’ and CS-5’ to
amplify different fragment size of class 1 integrons. The
primers, PCR conditions and reaction mixtures used
were as described previously [12].Detection of plasmid-mediated quinolone resistant, and
aminoglycoside resistant- genetic determinants
The assessment of plasmid mediated quinolone resistance
(PMQR) and aminoglycoside resistant determinants carried
by CRPA was conducted as described previously [13, 15].
All CRPA strains were screened by multiplex PCR for
qnr genes (qnrA, qnrB and qnrS). PCR amplification of
aac(6’)-Ib encoding aminoglycoside 6′-N-acetyltransferase
type Ib enzyme and aac(3)-II encoding 3-N-aminoglycoside
acetyltransferases genes was performed using primers that
amplify all variants.Sequencing of resistance genes
All amplified products obtained were sequenced to val-
idate their identities. Both strands of the purified ampli-
cons were sequenced with a Genetic Analyzer 3130x1
sequencer (Applied Biosystems, Foster City, CA, USA),
with the same primers used for PCR amplification. The
nucleotide and deduced protein sequences were analyzed
with the software available over the Internet at the
National Center for Biotechnology Information website
(www.ncbi.nlm.nih.gov).Genotyping of CRPA isolates by Pulsed-field gel
electrophoresis
Pulsed-field gel electrophoresis (PFGE) analysis was per-
formed according to the standardized protocol developed
by Durmaz et al. [16] using SpeI. The Dice similarity coeffi-
cient was calculated between pairs of lanes, and the strains
were grouped, using the dendrogram construction utility
Dendro UPGMA (Biochemistry and Biotechnology Depart-
ment, Rovirai Virgili University, Tarragona, Spain) (http://
genomes.urv.cat/UPGMA/index.php). The isolates were
considered to be genetically related if the Dice coefficient of
correlation was 80 % or greater.Analysis of data
To identify variables associated with CRPA, a risk factor
analysis was performed using a case–control study for-
mat. Demographics and hospitalization variables of
CRPA case patients were compared with patients with
carbapenem susceptible P. aeruginosa (CSPA). Data were
entered into a database using the SPSS 20.0 for Win-
dows (SPSS Inc, Chicago, USA). The χ2 test and the in-
dependent samples t test were used for categorical and
continuous variables, respectively. A stepwise multivari-
ate logistic regression was conducted to examine the as-
sociation of risk factors controlling for potential
confounders. The logistic model included all variables
for which a p value of < 0.1 was obtained in the multi-
variate analysis. A p value of <0.05 was considered as
significant.
Table 1 Characteristics of patients infected with carbapenem-
resistant P. aeruginosa and carbapenem-susceptible P. aeruginosa
Variable CRPA (n = 15) CSPA (n = 65) p-value
Age-years
Mean 47.54 ± 12.7 47.45 ± 20.88 0.5
Gender–n (%)
Female 5(33.34) 27(41.53) 0.57
Male 10(66.66) 38(58.46) 0.60
Sexe-ratio 0.5 0.68
Duration of hospitalization-days 82.5 ± 45.82 63.44 ± 48.82 0.04
Ward
Otorhinolaryngology 0 15(23.07) 0.06
Endocrinology 9(60) 36(53.85) 0.74
ICU-surgery 3(20) 6(9.23) 0.36
ICU-medecin 0 4(6.15) 1
Outpatient 3(20) 4(6.15) 0.12
Source
Diabetic ulcers 9(60) 47(70.76) 0.34
Urine 4(26.66) 5(7.7) 0.08
Blood 1(6.66) 0 0.18
Aspiration tracheal 1(6.66) 13(20) 0.45
Coexisting diseases
Trauma 3(20) 6(9.23) 0.36
Diabetes mellitus 7(46.66) 35(53.85) 0.5
Otitis 0 7(10.77) 0.03
Respiratory disease 0 4(6.15) 1
Renal disease 0 2(3.07) 1
Other 0 6(9.23) 0.5
Previous antibiotics use 11(73.34) 59(90.76) 0.03
Cephalosporin (third-generation) 10(66.67) 44(67.69) 1
Aminoglycoside 1(6.66) 12(18.46) 0.4
Fluroquinolone 0 2(3.07) 1
Without antibiotic therapy 4(26.66) 7(10.77) 0.2
Invasive devices 3(20) 12(18.46) 1
Urinary catheter 3(20) 2(3.07) 0.04
Intubation 0 5(7.7) 0.5
Intubation + urinary catheter 0 5(7.7) 0.5
Polymicrobial infection 9(60) 33(50.77) 0.5
K. pneumoniae 1(6.66) 1(1.53) 0.3
S. aureus 5(33.34) 6(9.23) 0.01
E. coli 2(13.33) 8(12.30) 1
S. aureus + E. coli 1(6.66) 4(6.15) 1
S. aureus + P. mirabilis 0 10(15.38) 0.19
S. aureus + K. pneumoniae 0 3(4.61) 1
Mortality 2(13. 33) 1(1.53) 0.09
CRPA:carbapenem-resistant P. aeruginosa, CSPA: carbapenem-susceptible
P. aeruginosa
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A total of 80 patients were included in this study and dis-
tributed in 40 % female and 60 % male (M:F ratio was 1.5).
Fifteen patients presented CRPA infection (18.75 %; 95 %
confidence interval: 10.2-27.3) and 65 patients had CSPA
infection. The median age was 45 years-old in the CRPA
group, and 51 in the CSPA group, with no significant differ-
ence, using parametric (for mean) or non-parametric (for
median) tests. The duration of hospitalization was different
between the groups, although it had a tendency to be pro-
longed in the CRPA group, with a median of 63.44 ±
48.82 days in the CSPA group and 82.5 ± 45.82 days in the
CRPA group. The infected patients were hospitalized in
various hospital units with the majority of patients from the
endocrinology (55 %), followed by the patients from the
otorhinolaryngology (18.75 %) and surgery (11.25 %) wards,
while the rest of the patients were from various other hos-
pital wards. According to anatomical location, the infec-
tions caused by P. aeruginosa were divided into infections
of skin, surgical site infections, and soft tissues (70 %), re-
spiratory tract infections (17.50 %), urinary tract infections
(11.25 %), and bloodstream infections (1.25 %). All the clin-
ical data are detailed in the Table 1. Even though several
variables were compared, the urinary catheter use, previous
use of antibiotics, and co-infection by Staphyloccocus aur-
eus were statistically significant. In the multivariate analysis
none of the risk factor for CRPA was identified. The treat-
ment of P. aeruginosa infection was incorrect in 57 of 80
patients (71.20 %) (Table 2). The mortality of patients with
P. aeruginosa infection was 1.53 % for patients with CSPA
and 13.34 % for patients with CRPA, without statistical
significance.
The antimicrobial susceptibility testing was done by disc
diffusion method to 80 clinical isolates of P. aeruginosa.
The resistant rates for β-lactam antibiotics including ticar-
cillin, ceftazidime, ticarcillin/clavulanic acid, aztreonam and
piperacillin were 61.25 %, 56.25 %, 56.25 %, 41.25 % and
36.25 %, respectively. The resistant rates for non-β-lactam
antibiotics including ciprofloxacin, colistin and gentamicin
were 43.75 %, 25 %, and 21.75 %, respectively. The degrees
of antibiotic resistance for all antibiotics tested were signifi-
cantly higher in the CRPA isolates, compared with CSPA
isolates (Table 3). Colistin and amikacin were the most ef-
fective antibiotics against CRPA isolates with a susceptibil-
ity of 93.90 % and 100 % respectively. CSPA isolates were
significantly more susceptible to ticarcillin/clavulanic acid
(51.56 % vs. 7 %), aztreonam (70.31 % vs. 7 %), gentamicin
(46.66 vs. 15.38 %) and ceftazidime (50 % vs. 13 %) com-
pared to CRPA isolates.
The MIC values for the imipenem varied widely
among the CRPA isolates. The ranges of the MIC values
were 8- > 32 μg/mL (Fig. 1). MBL screening with EDTA
and modified Hodge test was negative in all isolates.
PCR analysis was performed for all the CRPA isolates.
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penemase encoding genes; blaVIM, blaIMP, blaGES, blaKPC,
blaOXA-58, blaOXA-40, blaOXA-23 and blaOXA-51. Synergy
tests were performed using clavulanic acid-ticarcillin-,
aztreonam-, and ceftazidime-containing disks did not
give evidence of any inhibition of aztreonam and ceftazi-
dime resistance for all the CRPA isolates, ruling out the
production of ESBL. PCR detecting of carbenicillinase
encoding gene blaPSE-1 was positive in two isolates
(P.a29 and P.a30). AmpC over-expression was previously
reported to be highly correlated with ceftazidime resist-
ance. We found that AmpC over-expression was present
in 62 % of CRPA isolates and none gave positive PCR re-
sults for plasmid-mediated AmpC β-lactamase genes.
Among seven gentamicin resistant CRPA isolates, five
harboured aac(3)-II encoding 3-N-aminoglycoside
acetyl-transferases gene (P.a1, P.a2, P.a18, P.a29, P.a30).
The plasmid-mediated quinolone resistance genes, was
not found in the examined isolates. The class 1 integron
(Int1) was detected in two isolates (P.a29 and P.a30)
with PCR amplicons 1 kb in length. Sequence analysis ofTable 3 Comparison between CRPA and CSPA on the
susceptibility of antibiotics tested
Antibiotics Proportion of resistance
(%), (No. of resistant strains)
p-value
CRPA CSPA
Ticarcilline 100 % (15) 53 % (34) >0.0001
Ticarcilline + clavulanic acid 93 % (14) 48.44 % (31) 0.001
Ceftazidime 87 % (13) 50.00 % (32) 0.008
Aztreonam 93 % (14) 29.69 % (19) >0.0001
Piperacilline 87 % (13) 25.00 % (16) >0.0001
Ciprofloxacine 100 % (15) 31.25 % (20) >0.0001
Colistin 7 % (4) 24.61 (16) 1
Amikacin 0 % 0 %
Gentamicin 46.66 % (7) 15.38 % (10) 0.007
CRPA:carbapenem-resistant P. aeruginosa, CSPA: carbapenem-susceptible
P. aeruginosathese amplicons revealed the presence of the aadA7
gene cassette.
In the genotyping analysis, the DNA fingerprint pat-
terns of the 15 carbapenem-resistant isolates revealed
four distinct clones, as shown in Fig. 1. One of these
clones was represented by a single isolate (isolate P.a31,
clone C). The other two clones were represented by six
(clone A and B), and two (D) isolates, respectively. Clone
A and B were isolated from two different hospitals.
Clone A came from two different wards outpatients and
ICU wards, showing a wide MIC range (8- > 32 μg/mL),
and clone B which exclusively came from endocrinology
ward, showed a homogeneous MIC value (16 μg/mL).
The combination of PFGE results with hospital overlap
data in each ward, demonstrated from patient -to-patient
transmission in 8 (53.34 %) patients at endocrinology ward
(clone B and D). In contrast, the same isolates of other
clones were found in patients hospitalized in the same ward
within a few months of each other, indicating that the per-
sistence of the clone at the ward or hospital is still existing.
Discussion
Carbapenems are among the best choices for the treatment
of infections caused by multi-drug-resistant P. aeruginosa
(MDR- P. aeruginosa) isolates [1]. In recent years, Algeria
has been considered among the countries that reported
high rates of antimicrobial resistance [7, 8, 17]. In the
present study, there were high levels of resistance to all
commercially available antimicrobial agents among P. aeru-
ginosa isolated from Annaba Hospital; the rate of 18.75 %
CRPA isolates, this rate of carbapenem resistance reflects a
threat limiting the treatment options in our hospitals. The
rates of CRPA isolates varied by geographic region, speci-
men source, and selective pressure from antibiotics [18]. In
Algeria, Drissi et al. [17] concluded that P. aeruginosa iso-
lates exhibited the highest resistance levels to imipenem
(35 %) in the period between 2005–2007. Also Sefraoui et al.
[8] showed that among P. aeruginosa strains 39.32 % were
resistant to imipenem during the period 2009–2012. How-
ever, the CRPA frequency shown in the studied hospitals
during the period 2012–2013 was lower than those re-
ported in Algeria. Among the neighboring countries, such
as Libya, Tunisia and Egypt the occurrence of imipenem
resistant P. aeruginosa was reported often and it ranged
between 24.2 % and 39.34 % [19–21].
In our study, CRPA were more resistant to multiple
drugs than CSPA isolates, and the most effective anti-
biotic against CRPA isolates was amikacin and colistin.
These findings indicate that amikacin and colistin has
increasingly become the last viable therapeutic option
for MDR-Pseudomonas infections. The high percentage
of co-resistance to carbapenem and fluroquinolone is
relevant among the studied CRPA, highlighting the per-
centage of resistance to ciprofloxacin (100 %) that was
Fig. 1 Representative SpeI pulsed-field gel electrophoresis (PFGE) profiles of carbapenem–resistant P. aeruginosa isolates studied. A dendrogram
was generated with Dendro UPGMA ((http://genomes.urv.cat/UPGMA/index.php). The PFGE profile, the sex and age of patients infected, and
wards are indicated
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penem resistance in P. aeruginosa strains may result
from multiple mechanisms with or without the produc-
tion of carbapenemase [1]. Loss or under expression of
porin OprD is the most common mechanism of resist-
ance to carbapenems and is frequently associated with
efflux pumps and/or AmpC over expression [1, 22]. In
our study, none of the CRPA isolates found were posi-
tive for carbapenemase-producing genes, and the MIC
values for imipenem ranged between 8- > 32 μg/mL.
These results suggested the presence of other mecha-
nisms such as over-expression of the efflux pump or loss
of outer membrane porin. In addition, the mutational
disruption of oprD is the major emerging mechanism of
carbapenem resistance among P.aeruginosa isolates in
Algeria [7, 8]. Several previous studies have examined
the occurrence of aminoglycoside resistance mecha-
nisms in P. aeruginosa isolated from different countries
[1, 23, 24]. In our study, the rate of gentamicin resist-
ance found in CRPA (46.6 %) was much higher than
the rate that has been reported previously in Annaba
hospitals (28.09 %) [8]. The aac(3)-II was the only re-
sistance gene observed in this study. This result was in
accordance with what has been observed in different
studies in other countries, in which the transferable
aminoglycoside-modifying enzymes were the most frequent
mechanisms in aminoglycoside resistance in P. aeruginosa
[25, 1, 26]. The class I integron and carbenicillin hydrolys-
ing β-lactamases of Pseudomonas specific enzyme (PSE-1)
type were found in two CRPA isolates. These class I
integrons may play an important role in the develop-
ment of antimicrobial resistance and emergence of
MDR- P. aeruginosa [27].The risk factors for acquiring CRPA may be related to
the host condition, infection control practice, and anti-
microbial consumptions [28–30]. Regarding invasive
procedures, in our study urinary catheter is hypothesized
to be a risk factor for CRPA- infection. This was not sur-
prising, given that P.aeruginosa tends to make biofilm
on the surface of urinary catheters, and they increase the
risk of translocation of organisms to the urinary tract,
causing infection [18, 30, 31]. These results highlight the
need for improved measures to control nosocomial
infection and show that the manipulation of invasive de-
vices is one of the main procedures that require inter-
vention measures.
The length of hospital stay before isolation of CRPA
was also reported as the risk factor in this study. This re-
sult is consistent with many studies evaluating the rela-
tionship between acquisition of CRPA infection and the
length of stay [28, 30, 32, 33]. One possible explanation
for these findings is that patients who are in hospital for
longer periods of time have increased exposure to noso-
comial pathogens and, subsequently, are at increased
risk of being colonized by these organisms [28–30, 32].
A clonal dissemination of CRPA isolates with the pres-
ence of two important CRPA clones were observed in this
study. In our study, we defined cases of patient-to-patient
transmission on the basis of isolates with similar PFGE pat-
terns and an overlap in hospital stay. These cases which
were observed in 53.34 % patients at endocrinology ward
(clone B and D), suggest that patient-to-patient transmis-
sion is an important dissemination mechanism and has
contributed to the increased rate of resistance to carbapen-
ems. The patients admitted in endocrinology wards often
have compromised immune systems (all patients harboured
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(such as catheterization, intubation, blood collection, etc.)
and a high antimicrobial intake, which could have been pre-
disposing factors for infections and the spread of resistant
bacteria [30].
In parallel with other services presented in this study, the
spread of the pathogen can be explained by the fact that in
hospitals where the most serious infections occur, Pseudo-
monas can be spread too, on the hand of healthcare
workers or by an equipment that gets contaminated and is
not properly cleaned. These results suggest an exogenous,
preventable acquisition of P. aeruginosa, which should
stimulate research on policies of premises decontamination
and their impact on P. aeruginosa acquisition.
The differences between services can be explained by
differences in patient population and by differences in
the implementation of general measures of hygiene to
control cross-transmission between patients.
Patients in the current study were already hospitalized
in other wards and other hospitals; the movements of
patients between different hospital wards must therefore
also be considered.Limitations
As with any retrospective study, our study is not without
limitations, for the nature of retrospective design, the diag-
nosis and management of sepsis and antibiotic choice
were based on individual clinicians’ opinions. Our data
were collected from a single site, so institutional differ-
ences in prescribing patterns, antibiotic formularies, and
patient populations may affect the applicability of our
results to other institutions. On the other hand, because
active surveillance was not performed over the study
period, we cannot ensure that control patients did not
harbour CRPA. Our small sample size was another limita-
tion; it may have limited the detection of other risk factors.
Finally, the completed molecular characterization of car-
bapenem resistance mechanisms in CRPA isolated in this
study, such as the membrane permeability and efflux
mechanisms should be investigated.Conclusion
In conclusion, to the best of our knowledge, this is the first
report to identify risk factors in Algeria for P. aeruginosa
resistant to carbapenem. Our study confirmed that the
length of hospital stay is the major risk factor for CRPA, as
the same presence of invasive devices.
In addition, our result also demonstrate clonal dissemin-
ation of CRPA isolates, suggest cross-transmission as an
important dissemination mechanism and has contributed
to the increased rate of resistance to carbapenems. A clear
understanding of risk and the mechanism of carbapenem
resistance prevalent in a hospital is vital to devise tailor-made intervention strategies also; effective empiric therapy
for nosocomial infections can be rationally formulated.
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